GlassScriptPhysician profile
Solanch Diaz Roig
NPI 1033745229
$3,560.17
in general payments reported to CMS, 2019-2025
25 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $172 · 2023: $1,551 · 2024: $1,595 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,387.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,106.92 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $448.19 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.40 | 2022-2023 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $230.24 | 2022-2025 | Entyvio, Trintellix |
| Teva Pharmaceuticals USA, INC. | $184.96 | 2024-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $157.85 | 2023-2024 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $125.97 | 2024 | Auvelity |
| Qol Medical, LLC | $123.83 | 2022-2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $117.62 | 2023 | Linzess |
| Janssen Scientific Affairs, LLC | $112.80 | 2023 | Stelara |
| Noven Therapeutics, LLC | $112.64 | 2023-2025 | Xelstrym |
| Almatica Pharma LLC | $102.59 | 2023-2024 | Loreev Xr, Teriparatide, Gralise |
| Lundbeck LLC | $74.06 | 2024-2025 | Rexulti |
| Braintree Laboratories, INC. | $60.96 | 2023 | Sutab |
| Vanda Pharmaceuticals INC. | $47.82 | 2024 | Hetlioz, Fanapt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $46.79 | 2024-2025 | Ingrezza |
| Evoke Pharma, INC. | $45.04 | 2023 | Gimoti |
| Intercept Pharmaceuticals, INC. | $43.16 | 2023 | Ocaliva |
| Ardelyx, INC. | $29.95 | 2023 | Ibsrela |
| Neos Therapeutics, LP | $27.53 | 2023-2024 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.61 | 2024 | Caplyta |
| Tris Pharma INC | $22.23 | 2024 | Dyanavel Xr |
| Daiichi Sankyo INC. | $18.70 | 2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $15.96 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $14.35 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solanch Diaz Roig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.